TIMOTHY L. MOORE - Corporate Board Profile

CERUS CORP

Filing Date	Source Excerpt
2019-04-26	Timothy L. Moore, 57, has served as a member of our Board since September 2018, filling the vacancy left by our former director, Bruce Cozadd. Mr. Moore is currently Executive Vice President, Technical Operations of Kite Pharma, a Gilead Company. Prior to Kite, he spent more than 12 years at Genentech, a Roche Company, most recently as Senior Vice President, Head of Global Technical Operations – Biologics and a member of the Genentech Executive Committee. While at Genentech, he oversaw global leadership for more than 7,500 professionals across 10 internal sites and managed more than 30 contract manufacturing organizations, including end to end quality supply performance of more than 20 biological products. Mr. Moore is currently a member of the board of directors FusionKite, a joint venture between Gilead Sciences, Inc. and Fusion Pharmaceuticals Inc. He holds a Bachelor of Science, Chemical Engineering from Tulsa University and an M.S. from Northwestern University.
2020-04-24	Timothy L. Moore, 58, has served as a member of our Board since September 2018. ... The Board has three standing committees: an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee. ... The following table provides membership and meeting information for fiscal 2019 for each of the Board committees: Timothy L. Moore - Audit Committee. ... The Compensation Committee currently consists of Ms. Schulze, Dr. Witney, and Messrs. Swisher and Moore. ... The following table shows for the fiscal year ended December 31, 2019 certain information with respect to the compensation of all non-employee directors of Cerus who served in such capacity during 2019. Timothy L. Moore compensation: $48,000.
2021-04-23	Timothy L. Moore, 59, has served as a member of our Board since September 2018... The Compensation Committee is currently composed of four directors: Ms. Schulze (Chair), Dr. Witney, and Messrs. Swisher and Moore... The following table shows for the fiscal year ended December 31, 2020 certain information with respect to the compensation of all non-employee directors of Cerus who served in such capacity during 2020... Timothy L. Moore Fees Earned or Paid in Cash($) 53,000, Option Awards($) 87,938, Stock Awards($) 84,262, Total($) 225,200.
2022-04-22	Timothy L. Moore, 60, has served as a member of our Board since September 2018... The Compensation Committee is currently composed of three directors: Ms. Schulze (Chair), Dr. Witney, and Mr. Moore... The following table shows for the fiscal year ended December 31, 2021 certain information with respect to the compensation of all non-employee directors of Cerus who served in such capacity during 2021... Timothy L. Moore: Fees Earned or Paid in Cash $53,000, Option Awards $83,674, Stock Awards $83,671, Total $220,345.
2023-04-28	Timothy L. Moore, 61, has served as a member of our Board since September 2018. The Compensation Committee is currently composed of three directors: Ms. Schulze (Chair), Dr. Witney, and Mr. Moore, all of whom were on the Compensation Committee for all of 2022. The Audit Committee met four times during the fiscal year.
2024-04-26	Timothy L. Moore, 62, has served as a member of our Board since September 2018. ... Under our director compensation program in effect for 2023, each non-employee director was entitled to an annual grant of RSUs on the date of each of our annual meetings ... each of our non-employee directors other than Dr. Shan received an RSU grant covering 40,000 shares on the date of the 2023 Annual Meeting. ... The number of shares subject to the RSU awards was determined in 2023 by dividing the target dollar value ($200,000) by a price of $5.00 per share ... The aggregate grant date fair value of the annual RSU awards for 2023 granted on June 7, 2023, calculated in accordance with Topic 718 ... The total for Mr. Moore is $154,600.